A Phase 3 interventional study of Pomalidomide and Dexamethasone in Multiple Myeloma, sponsored by Celgene. Completed at 112 sites in 20 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-01-10.
Sponsored by Celgene (part of Bristol-Myers Squibb) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 102 studies testing pomalidomide in Multiple Myeloma — 15 open to participants now, 39 under way, 9 of them phase 3. pomalidomide · Multiple Myeloma.
Among the 102 studies testing pomalidomide in Multiple Myeloma, this one is the 4th largest by enrollment, is one of 7 that started in 2012, is one of 17 in phase 3, and was the 17th registered.
3,763 studies on the registry are indexed under Multiple Myeloma; 770 are open to participants now.
Browse Multiple Myeloma studies →15 of the 102 studies testing pomalidomide in Multiple Myeloma are open now, in 12 countries. Recruiting first, the newest first:
Qilu Pharmaceutical Co., Ltd. · Sites in China
Ages 18+
Shandong New Time Pharmaceutical Co., LTD · Sites in China
Ages 18+
Massachusetts General Hospital · Sites in United States
Ages 18+
University of Chicago · Sites in United States
Ages 18+
Celgene · Sites in United States, Argentina, Australia and 26 more countries
Ages 18+
By country, each count listing its studies:
pomalidomide: first FDA approval 2013 (POMALYST), first EMA approval 2013. What it is approved for, and how studies give it, is on its page →
Of the 585 Multiple Myeloma studies recruiting now, 430 (74%) set no upper age limit and 106 (18%) stop at 75 or younger; 36 take children under 18; 24 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
102 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 26 · Phase 2 75 · Phase 3 17 · Phase 4 2
First in 2007; this study’s year is marked. 7 started in 2012.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 682 is above the median of 41 across 3,008 interventional studies indexed under Multiple Myeloma.
Median enrollment 50 across the 102 interventional studies. Of the 48 that completed or were terminated, 24 (50%) have results posted.
This tab as a report to print or save as PDF → With an account.
35 of 102 have an industry lead sponsor. The 10 most frequent:
This study is registered under Celgene, one of the names counted as Bristol-Myers Squibb. Under that name alone:
Celgene is the lead sponsor of 428 studies on the registry; 12 are open to participants now.
Of its 104 completed or terminated interventional studies of FDA-regulated products, 30 (29%) have results posted.
149 studies in Multiple Myeloma by Bristol-Myers Squibb: 9 open now, 18 under way, 6 of them phase 3. Of 120 finished, 43 (36%) have results posted.
Among the 149 studies in Multiple Myeloma by Bristol-Myers Squibb, this one is the 7th largest by enrollment of the 108 interventional ones that give a count, is one of 13 that started in 2012, is one of 30 in phase 3, and was the 53rd registered.
Bristol-Myers Squibb’s Multiple Myeloma studies by the year they started, since 2001.
10 of the studies testing pomalidomide in Multiple Myeloma that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05519085Phase 3CelgeneA Study to Evaluate Mezigdomide, Bortezomib and Dexamethasone (MEZIVd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) | 2027-01-10 |
| NCT05455320Phase 3Janssen Research & Development, LLCA Study Comparing Talquetamab in Combination With Daratumumab or in Combination With Daratumumab and Pomalidomide Versus Daratumumab in Combination With Pomalidomide and Dexamethasone in Participants With Multiple Myeloma That Returns After Treatment or is Resistant to Treatment | 2027-07-30 |
| NCT02718833Massachusetts General HospitalA Study of Elotuzumab With Pomalidomide, Bortezomib, and Dexamethasone in Relapsed Multiple Myeloma | 2026-12 |
| NCT04883242University of WashingtonIsatuximab, Carfilzomib, Pomalidomide, and Dexamethasone for the Treatment of Relapsed or Refractory Multiple Myeloma | 2026-12-31 |
| NCT04508790City of Hope Medical CenterLeflunomide, Pomalidomide, and Dexamethasone for the Treatment of Relapsed or Refractory Multiple Myeloma | 2027-02-14 |
Add all 10 to your calendar (.ics) → With an account.
Among the 102 studies testing pomalidomide in Multiple Myeloma, from their registry updates:
Among Bristol-Myers Squibb’s 149 in Multiple Myeloma:
This tab as a report to print or save as PDF → With an account.
The primary purpose of the study is to evaluate the safety and efficacy and to generate PK and biomarker data for the combination of pomalidomide and low-dose dexamethasone in patients with refractory or relapsed and refractory multiple myeloma.
The study consists of a Screening phase within 28 days prior to cycle 1 day 1, a Treatment phase and a Follow-up phase which starts within 28 days of discontinuation from study treatment, every 3 months for up to 5 years.
In addition, the collection of steady-state PK data from a large population will enable robust population PK and assess Pomalidomide exposure response analyses.
The exploratory objectives of the study are to investigate potential markers predictive of POM response or resistance and pharmacodynamic markers.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Allogeneic and autologous transplant
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Pomalidomide 4mg by mouth (PO) daily days 1 through 21 of a 28 day cycle and dexamethasone 40mg/day PO for those ≤75 years of age or 20mg/day for those greater than 75 years of age on Days 1, 8, 15 and 22 of a 28 day cycle.
Drug: Pomalidomide · Drug: Dexamethasone
Oral Pomalidomide at the starting dose of 4 mg on Days 1-21 of a 28-day cycle
Oral Low dose Dexamethasone at the starting dose of 40mg/day (≤ 75 years old) or 20 mg/day (\> 75 years old) on Days 1, 8, 15 and 22 of a 28-day cycle.
Number of Participants With Treatment Emergent Adverse Events (TEAE)
An adverse event (AE) is any noxious, unintended, or untoward medical occurrence that may appear or worsen in a subject during the course of a study. It may be a new intercurrent illness, a worsening concomitant illness, an injury, or any concomitant impairment of the subject's health, regardless of etiology. Any worsening (i.e., any significant adverse change in the frequency or intensity of a pre- existing condition) was considered an AE. The severity of AEs were graded based on the symptoms according to version 4.0 of the National Cancer Institute Common Terminology Criteria for Adverse Events. Second primary malignancies were monitored as events of interest and considered as part of the assessment of AEs. A SAE = AE occurring at any dose that: * Results in death; * Is life-threatening * Requires inpatient hospitalization or prolongation of existing hospitalization * Results in persistent or significant disability/incapacity * Is a congenital anomaly/birth defect
Time frame: From the first dose of study treatment up to 28 days following the last dose of study treatment. The median duration of treatment with pomalidomide and LD-dex was 21.4 weeks.
Overall Response
Overall response rate (ORR) was defined as the percentage of participants with a stringent complete response (sCR), complete response (CR), very good partial response (VGPR) or partial response (PR) according to the International Myeloma Working Group uniform response criteria (IMWG URC) assessed by the Investigator. Responses must have been confirmed at at least 2 consecutive assessments before the institution of any new therapy with no known evidence of progressive or new bone lesions
Time frame: Response was assessed at each treatment cycle and at treatment discontinuation; median duration of treatment with pomalidomide and LD-dex was 21.4 weeks
Time to Response
Time to response was defined as the time from treatment enrollment to the first documentation of response (sCR, CR, VGPR or PR) based on IMWG criteria.
Time frame: Response was assessed at each treatment cycle and at treatment discontinuation; median duration of treatment with pomalidomide and LD-dex was 21.4 weeks
Kaplan Meier Estimate of Duration of Response
Duration of response, calculated for responders only, was defined as time from the initial documented response (SCR, CR, VGPR or PR) to the first confirmed disease progression, or death if no disease progression was recorded. Participants without a documented progression were censored at the time of their last tumor assessment.
Time frame: From enrollment to the end of follow-up; median time on follow-up was 10.9 (range 0 - 81) months
Kaplan Meier Estimate of Progression Free Survival (PFS) According to the European Medicines Agency Guidelines
Progression free survival was calculated as the time from study enrollment, defined as the IVRS enrollment date, until either PD or death (any cause). Participants without an event (either a documented PD or death) at the time of study end were censored at the time of their last documented disease assessment or at the IVRS enrollment date if no disease assessment was conducted.
Time frame: From enrollment to the end of follow-up; median time on follow-up was 10.9 (range 0 - 81) months
Kaplan Meier Estimate of Time to Progression
Time to progression was calculated as the time from study enrollment until first recorded disease progression as determined by the site investigator based on the IMWG criteria, or until death due to progression. Participants not experiencing a documented progression were censored at the time of their last tumor assessment (or at the time of trial enrollment if no assessment was conducted).
Time frame: From enrollment to the end of follow-up; median time on follow-up was 10.9 (range 0 - 81) months
Kaplan Meier Estimate of Overall Survival (OS)
Overall survival was calculated as the time from study enrollment, defined as the IVRS enrollment date, until death due to any cause. Participants who did not have death data at the time of study end/analysis were censored at the time they were last known to be alive.
Time frame: From enrollment to the end of follow-up; median time on follow-up was 10.9 (range 0 - 81) months
Pomalidomide Exposure - Apparent (Oral) Clearance (CL/F)
Pharmacokinetic (PK) parameters are derived from pomalidomide concentration versus time data.
Time frame: Cycles 1, 2, 3, 4, 5, 6
Pomalidomide Exposure - Apparent Volume of Distribution (V/F)
Pharmacokinetic (PK) parameters are derived from Pomalidomide concentration versus time data.
Time frame: Cycles 1, 2, 3, 4, 5, 6
Cytogenetic Analysis
Cytogenetic analysis was to be performed using fluorescence in situ hybridization (FISH) methodology at a local laboratory, to evaluate the relationship between cytogenetic profiles and the combination of POM and LD-DEX in terms of response and outcome.
Time frame: Study entry
The study was conducted at 112 sites: 4 in Austria, 7 in Belgium, 3 in Denmark, 1 in Estonia, 2 in Finland, 13 in France, 17 in Germany, 1 in Greece, 3 in Ireland, 15 in Italy, 5 in the Netherlands, 2 in Norway, 3 in Poland, 4 in Portugal, 1 in Slovakia, 15 in Spain, 2 in Sweden, 3 in Switzerland, 2 in Turkey, and 9 in the United Kingdom.
| Milestone | Pomalidomide Plus Low Dose Dexamethasone (LD-Dex) |
|---|---|
| Started | 682 |
| Received study treatment | 676 |
| Completed | 0 |
| Not completed | 682 |
| Withdrew: Lack of efficacy | 2 |
| Withdrew: Lost to follow-up | 1 |
| Withdrew: Progressive disease | 504 |
| Withdrew: Death | 57 |
| Withdrew: Adverse event | 52 |
| Withdrew: Miscellaneous | 31 |
| Withdrew: Withdrawal by subject | 21 |
| Withdrew: Transition to commercial treatment | 8 |
| Withdrew: Participants did not receive study drug | 6 |
An adverse event (AE) is any noxious, unintended, or untoward medical occurrence that may appear or worsen in a subject during the course of a study. It may be a new intercurrent illness, a worsening concomitant illness, an injury, or any concomitant impairment of the subject's health, regardless of etiology. Any worsening (i.e., any significant adverse change in the frequency or intensity of a pre- existing condition) was considered an AE. The severity of AEs were graded based on the symptoms according to version 4.0 of the National Cancer Institute Common Terminology Criteria for Adverse Events. Second primary malignancies were monitored as events of interest and considered as part of the assessment of AEs. A SAE = AE occurring at any dose that: * Results in death; * Is life-threatening * Requires inpatient hospitalization or prolongation of existing hospitalization * Results in persistent or significant disability/incapacity * Is a congenital anomaly/birth defect
| Participants | Pomalidomide Plus Low Dose Dexamethasone (LD-Dex) |
|---|---|
| ≥ TEAE | 673 |
| ≥ 1 TEAE Related to Pomalidomide (POM) | 527 |
| ≥ 1 TEAE Related to LD-Dex | 448 |
| ≥ 1 TEAE Related to Either POM or LD-Dex | 575 |
| ≥ 1 Grade (Gr) 3 or 4 TEAE | 606 |
| ≥ 1 Gr 3 or 4 TEAE Related to (R/T) POM | 417 |
| ≥ 1 Gr 3 or 4 TEAE R/T LD-Dex | 226 |
| ≥ 1 Gr 3 or 4 TEAE R/T Either POM or LD-Dex | 448 |
| ≥ 1 Grade 5 TEAE | 127 |
| ≥ 1 Grade 5 TEAE R/T POM | 14 |
| ≥ 1 Grade 5 TEAE R/T LD-Dex | 16 |
| ≥ 1 Grade 5 TEAE R/T either POM or LD-Dex | 18 |
| ≥ 1 Serious TEAE | 448 |
| ≥ 1 Serious TEAE R/T POM | 187 |
| ≥ 1 Serious TEAE R/T LD-Dex | 146 |
| ≥ 1 Serious TEAE R/T Either POM or LD-Dex | 215 |
| ≥ 1 Serious TEAE Leading to (L/T)Stopping of POM | 36 |
| ≥ 1 Serious TEAE L/T Stopping of LD-Dex | 34 |
| ≥1 Serious TEAE L/T Stopping either POM or LD-Dex | 37 |
| ≥ 1 TEAE L/T to Stopping of POM | 54 |
| ≥ 1 TEAE L/T to Stopping of LD-DEX | 61 |
| ≥ 1 TEAE L/T to Stopping of Either POM or LD-DEX | 63 |
| ≥1 Study Drug Related TEAE (L/T) Stopping POM | 30 |
| ≥1 Study Drug Related TEAE L/T Stopping LD-Dex | 19 |
| ≥1 Drug Related TEAE L/T Stopping LD-Dex or POM | 38 |
| ≥ 1 TEAE L/T to Reduction (R/D) of POM | 164 |
| ≥ 1 TEAE L/T to R/D of LD-DEX | 150 |
| ≥ 1 TEAE L/T to R/D of Either POM or LD-DEX | 244 |
| ≥ 1 Study Drug Related TEAE L/T to R/D of POM | 142 |
| ≥ 1 Study Drug Related TEAE L/T to R/D of LD-DEX | 135 |
| ≥1 StudyDrug Related TEAE L/T to R/D POM or LD-DEX | 224 |
| ≥ 1 TEAE L/T to Interruption (I/R) of POM | 455 |
| ≥ 1 TEAE L/T to I/R of LD-DEX | 434 |
| ≥ 1 TEAE L/T to I/R of either POM or LD-DEX | 470 |
| ≥ 1 Study Drug Related TEAE L/T to I/R of POM | 294 |
| ≥ 1 Study Drug Related TEAE L/T to I/R of LD-DEX | 185 |
| ≥1 StudyDrug Related TEAE L/T to I/R POM or LD-DEX | 333 |
Overall response rate (ORR) was defined as the percentage of participants with a stringent complete response (sCR), complete response (CR), very good partial response (VGPR) or partial response (PR) according to the International Myeloma Working Group uniform response criteria (IMWG URC) assessed by the Investigator. Responses must have been confirmed at at least 2 consecutive assessments before the institution of any new therapy with no known evidence of progressive or new bone lesions
| Percentage of Participants | Pomalidomide Plus Low Dose Dexamethasone (LD-Dex) |
|---|---|
| Overall Response | 33.4 (29.9 to 37.1) |
Time to response was defined as the time from treatment enrollment to the first documentation of response (sCR, CR, VGPR or PR) based on IMWG criteria.
| Weeks | Pomalidomide Plus Low Dose Dexamethasone (LD-Dex) |
|---|---|
| Time to Response | 8.1 (2 to 112) |
Duration of response, calculated for responders only, was defined as time from the initial documented response (SCR, CR, VGPR or PR) to the first confirmed disease progression, or death if no disease progression was recorded. Participants without a documented progression were censored at the time of their last tumor assessment.
| Months | Pomalidomide Plus Low Dose Dexamethasone (LD-Dex) |
|---|---|
| Kaplan Meier Estimate of Duration of Response | 7.9 (6.48 to 8.78) |
Progression free survival was calculated as the time from study enrollment, defined as the IVRS enrollment date, until either PD or death (any cause). Participants without an event (either a documented PD or death) at the time of study end were censored at the time of their last documented disease assessment or at the IVRS enrollment date if no disease assessment was conducted.
| Months | Pomalidomide Plus Low Dose Dexamethasone (LD-Dex) |
|---|---|
| Kaplan Meier Estimate of Progression Free Survival (PFS) According to the European Medicines Agency Guidelines | 4.6 (3.91 to 4.90) |
Time to progression was calculated as the time from study enrollment until first recorded disease progression as determined by the site investigator based on the IMWG criteria, or until death due to progression. Participants not experiencing a documented progression were censored at the time of their last tumor assessment (or at the time of trial enrollment if no assessment was conducted).
| Months | Pomalidomide Plus Low Dose Dexamethasone (LD-Dex) |
|---|---|
| Kaplan Meier Estimate of Time to Progression | 4.8 (4.27 to 5.56) |
Overall survival was calculated as the time from study enrollment, defined as the IVRS enrollment date, until death due to any cause. Participants who did not have death data at the time of study end/analysis were censored at the time they were last known to be alive.
| Months | Pomalidomide Plus Low Dose Dexamethasone (LD-Dex) |
|---|---|
| Kaplan Meier Estimate of Overall Survival (OS) | 11.9 (10.65 to 13.41) |
Pharmacokinetic (PK) parameters are derived from pomalidomide concentration versus time data.
| Liters/hour | Pomalidomide Plus Low Dose Dexamethasone (LD-Dex) |
|---|---|
| Pomalidomide Exposure - Apparent (Oral) Clearance (CL/F) | 6.02 (5.67 to 6.48) |
Pharmacokinetic (PK) parameters are derived from Pomalidomide concentration versus time data.
| Liters | Pomalidomide Plus Low Dose Dexamethasone (LD-Dex) |
|---|---|
| Pomalidomide Exposure - Apparent Volume of Distribution (V/F) | 75.10 (63.57 to 89.17) |
Cytogenetic analysis was to be performed using fluorescence in situ hybridization (FISH) methodology at a local laboratory, to evaluate the relationship between cytogenetic profiles and the combination of POM and LD-DEX in terms of response and outcome.
No measurements were reported for this outcome.
Collected over All-cause mortality is reported from enrollment until the end of follow-up; median time on follow-up was 10.9 (range 0 - 81) months. Adverse events are reported from first dose of study drug up to 28 days after last dose; median duration of treatment was 21.4 weeks.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Pomalidomide Plus Low Dose Dexamethasone (LD-Dex) | 598/682 (87.7%) | 448/676 (66.3%) | 646/676 (95.6%) |
| Event | Pomalidomide Plus Low Dose Dexamethasone (LD-Dex) |
|---|---|
| PneumoniaInfections and infestations | 117/676 |
| General physical health deteriorationGeneral disorders | 45/676 |
| PyrexiaGeneral disorders | 41/676 |
| Febrile neutropeniaBlood and lymphatic system disorders | 34/676 |
| HypercalcaemiaMetabolism and nutrition disorders | 30/676 |
| Acute kidney injuryRenal and urinary disorders | 26/676 |
| Renal failureRenal and urinary disorders | 23/676 |
| Lower respiratory tract infectionInfections and infestations | 22/676 |
| NeutropeniaBlood and lymphatic system disorders | 20/676 |
| Atrial fibrillationCardiac disorders | 17/676 |
| Event | Pomalidomide Plus Low Dose Dexamethasone (LD-Dex) |
|---|---|
| NeutropeniaBlood and lymphatic system disorders | 382/676 |
| AnaemiaBlood and lymphatic system disorders | 327/676 |
| ThrombocytopeniaBlood and lymphatic system disorders | 236/676 |
| FatigueGeneral disorders | 197/676 |
| PyrexiaGeneral disorders | 178/676 |
| ConstipationGastrointestinal disorders | 163/676 |
| AstheniaGeneral disorders | 155/676 |
| CoughRespiratory, thoracic and mediastinal disorders | 141/676 |
| DiarrhoeaGastrointestinal disorders | 118/676 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 117/676 |
The intent to treat (ITT) population was defined as all enrolled participants (participants who received an interactive voice response system (IVRS) enrollment date) regardless of whether they received any investigational product (IP) or not.
| Age, Continuous(Years) | Pomalidomide Plus Low Dose Dexamethasone (LD-Dex) |
|---|---|
| Mean | 65.4 ± 9.10 |
| Sex: Female, Male(Participants) | Pomalidomide Plus Low Dose Dexamethasone (LD-Dex) |
|---|---|
| Female | 301 |
| Male | 381 |
| Ethnicity (NIH/OMB)(Participants) | Pomalidomide Plus Low Dose Dexamethasone (LD-Dex) |
|---|---|
| Hispanic or Latino | 52 |
| Not Hispanic or Latino | 626 |
| Unknown or Not Reported | 4 |
| Race/Ethnicity, Customized(Participants) | Pomalidomide Plus Low Dose Dexamethasone (LD-Dex) |
|---|---|
| Asian | 3 |
| Black or African American | 4 |
| White | 669 |
| Other | 2 |
| Missing | 4 |
| Eastern Cooperative Oncology Group (ECOG) Performance Status(Participants) | Pomalidomide Plus Low Dose Dexamethasone (LD-Dex) |
|---|---|
| 0 = Fully active, no restrictions | 295 |
| 1 = Restricted activity but ambulatory | 319 |
| 2 = Ambulatory and capable of all self-care | 67 |
| 3 = Limited self-care | 1 |
| 4 = Completely disabled | 0 |
| Time since diagnosis(Years) | Pomalidomide Plus Low Dose Dexamethasone (LD-Dex) |
|---|---|
| Mean | 6.15 ± 3.649 |
| Beta 2 Microglobulin(mg/L) | Pomalidomide Plus Low Dose Dexamethasone (LD-Dex) |
|---|---|
| Mean | 5.48 ± 4.713 |
| Serum Light Chain Type(Participants) | Pomalidomide Plus Low Dose Dexamethasone (LD-Dex) |
|---|---|
| Kappa | 364 |
| Lambda | 230 |
| No Serum Light chain Type Detected | 16 |
| Test Not Performed | 72 |
3 further baseline measures are reported on the registry.
Showing the first 100 of 112 sites across 20 countries. Choose a country and city above to see the rest.
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Nov 2012 to primary completion in Dec 2019, 85 months.
Results were first posted in Jan 2022, 2 years after primary completion.
Of 107 industry-sponsored phase 3 interventional studies under Multiple Myeloma, half reached primary completion within 45 months of starting (the median), counting those still running; a quarter within 30 and three quarters within 66. This study's 85 months is above that.
Counting every sponsor, half of 179 studies reached it within 55 months; a quarter within 34 and three quarters within 95.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Pomalidomide